At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
A research team at the Princess Margaret Cancer Centre co-led by affiliate scientist Dr. Michael Moran and Senior Scientist
Dr. Ming-Sound Tsao has shown that laboratory models of lung cancer closely mirror the behavior of human tumours.
"Non-small cell lung cancer remains the leading cause of cancer deaths worldwide," explains Dr. Tsao. "While there are several anti-cancer agents aimed at genetic mutations, most of the tumours do not harbour these targetable mutations and new effective anti-cancer agents are still much needed."
Using tumour samples from patients at the time of diagnosis and when cancer had returned, the research team implanted and successfully grew 137 tumours in laboratory models known as patient-derived xenografts. These models were established using two of the most common and aggressive types of lung cancer: adenocarcinoma and squamous cell cancer.
The research team then extensively studied the genetics and proteins present and used this information to construct molecular profiles of the tumours. Through analyzing the profiles, they found that the laboratory models closely mirrored human disease. The researchers also confirmed that the models had genetic mutations that are known to promote cancer cell growth, such as those in the KRAS and EGFR genes.
Going further, the team looked at modifications to genes known as epigenetic changes that govern whether genes were turned on or off. These analyses also confirmed that laboratory models matched up with what is observed in human cancer.
"Because these models so closely mirror the profiles of human disease, they represent a gold-standard for testing the biology of deadly lung cancers," explains co-senior author Dr. Moran, who is also professor in the Department of Molecular Genetics at University of Toronto (U of T) and a Senior Scientist at SickKids Research Institute. "Taking this into account, we took a deep dive into the protein makeup, or proteotype, of lung cancer in our laboratory models.
"We did this to see if the set of proteins in these cancer models could provide new insight into human disease."
By comprehensively examining the proteins in the laboratory models, the research team discovered three adenocarcinoma and two squamous cell carcinoma proteotypes that were each associated with different patient outcomes.
"Our findings show that laboratory models not only closely reflect non-small cell lung cancer in patients, but they can also be used to provide new insight into treatment outcomes," Dr. Tsao said in summarizing the findings.
"Laboratory models can help us look more closely at the bigger picture – to consider genetics as well as the protein landscape – so that we can identify anti-cancer therapies that move beyond targeting single mutations," said Dr. Tsao, who is also at U of T the M. Qasim Choksi Chair in Lung Cancer Translational Research, and a professor in the departments of Medical Biophysics, and Laboratory Medicine and Pathobiology.
This work was supported by the province of Ontario, the Canadian Cancer Society, the Canadian Institutes of Health Research, the Hospital for Sick Children (SickKids), the National Sciences and Engineering Research Council of Canada, the Terry Fox Foundation and The Princess Margaret Cancer Foundation.